| 1 0 (0%) | 06-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.53 |
1-year : | 13.08 |
| Resists | First : | 7.3 |
Second : | 11.19 |
| Pivot price | 7.9 |
|||
| Supports | First : | 1 |
Second : | 0.83 |
| MAs | MA(5) : | 7.73 |
MA(20) : | 7.87 |
| MA(100) : | 6.8 |
MA(250) : | 9.09 |
|
| MACD | MACD : | -0.1 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 43.6 |
D(3) : | 61.7 |
| RSI | RSI(14): 23.2 |
|||
| 52-week | High : | 20.39 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ANGN ] has closed below the lower bollinger band by 37.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ANGN ] is to continue within current trading range. It is unclear right now based on current values. 245.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.06 - 1.07 | 1.07 - 1.07 |
| Low: | 0.99 - 0.99 | 0.99 - 1 |
| Close: | 0.99 - 1 | 1 - 1.01 |
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.
Fri, 02 Jun 2023
Angion Biomedica to rise 1,000% at the open - a purely nominal change, no worries - Dhaka Tribune
Thu, 01 Jun 2023
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split - GlobeNewswire
Wed, 18 Jan 2023
Angion (ANGN) Down on Merger Agreement With Private Biotech - Yahoo Finance
Tue, 17 Jan 2023
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Angion Biomedica Corp (Nasdaq - ANGN) - GlobeNewswire
Tue, 17 Jan 2023
Elicio Therapeutics and Angion Enter into Definitive Merger Agreement - GlobeNewswire
Wed, 29 Jun 2022
Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 2.09e+007 (%) |
| Held by Institutions | 33 (%) |
| Shares Short | 55 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.039e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 148.2 % |
| Return on Equity (ttm) | -20.9 % |
| Qtrly Rev. Growth | 653000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -90.79 |
| EBITDA (p.s.) | -2.63333e+007 |
| Qtrly Earnings Growth | -10.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.45 |
| Dividend | 0 |
| Forward Dividend | 63650 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|